University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most ...
Jan 7, 2014
0
0
Cancer Research UK -funded scientists have discovered that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer, reveals research published in Oncogene ...
Aug 13, 2013
0
0
Cancer Research UK scientists are the first to use an efficient new screening strategy to identify gene faults in tumour cells that are possible drug targets for the most common form of lung cancer, according to new research ...
Jul 9, 2013
0
0
The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers. Anaplastic ...
Jul 1, 2013
0
0
ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma ...
Jun 25, 2013
0
0
A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current ...
May 28, 2013
0
0
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps ...
Apr 9, 2013
0
0
Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published ...
Apr 3, 2013
0
0
A drug that indirectly impairs the function of several cancer-driving proteins, including anaplastic lymphoma kinase (ALK), may be an effective new treatment for patients with ALK—positive non-small cell lung cancer.
Mar 26, 2013
0
0
Patients with non-small-cell lung cancer survive longer if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients published in the cancer journal Annals of Oncology today.
Jan 8, 2013
0
0
